Histopathologic Evaluation of Radio-Protective Effect of Hesperidin on the Liver of Sprague Dawely Rats.
Capillarization
Gamma Rays
Hesperidin
Hyperemia
Radio-Protector
Journal
Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
09
09
2017
accepted:
04
12
2017
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
Hesperidin is a bioflavonoid glycoside mainly found in citrus fruit and has been shown radio-protective potential in various measurement systems. In this article aims to investigate the radio-protective effect of hesperidin on the liver of Sprague Dawely rats. In this clinical study, 40 male rats were selected randomly and divided into 8 groups. Group 1 did not receive radiation and hesperidin (sham control). Group 2 received only 100 mg/kg body weight (b.w) of hesperidin for 7 consecutive days (HES group); group 3 exposed to dose of 2Gy whole body gamma radiation (2Gy group), and group 4 and 5 received 50 and 100 mg/kg b.w of HES for 7 consecutive days before 2 Gy gamma radiation, respectively.Group 6 exposed to dose of 8Gy gamma radiation (8Gy group); group 7 and 8 received 50 and 100 mg/kg b.w of HES for 7 days before 8Gy gamma irradiation, respectively. Histopathological evaluation was perfomred 24 hours after radiation. Administration of hesperidin (50 mg/kg b.w, 7 days) before 2Gy of gamma irradiation led to remove inflammatory mononuclear cells in the portal space. Microscopic findings in the groups receiving two doses of hesperidin (50 and 100 mg/kg b.w, orally, 7 days), before 8Gy of gamma radiation, were similar in a way that extreme dilation of central veins to be seen, however, there was no capillarization. HES can be offered as a suitable radio-protector in radiotherapy patients and radiation workers.
Sections du résumé
BACKGROUND
BACKGROUND
Hesperidin is a bioflavonoid glycoside mainly found in citrus fruit and has been shown radio-protective potential in various measurement systems.
OBJECTIVE
OBJECTIVE
In this article aims to investigate the radio-protective effect of hesperidin on the liver of Sprague Dawely rats.
MATERIAL AND METHODS
METHODS
In this clinical study, 40 male rats were selected randomly and divided into 8 groups. Group 1 did not receive radiation and hesperidin (sham control). Group 2 received only 100 mg/kg body weight (b.w) of hesperidin for 7 consecutive days (HES group); group 3 exposed to dose of 2Gy whole body gamma radiation (2Gy group), and group 4 and 5 received 50 and 100 mg/kg b.w of HES for 7 consecutive days before 2 Gy gamma radiation, respectively.Group 6 exposed to dose of 8Gy gamma radiation (8Gy group); group 7 and 8 received 50 and 100 mg/kg b.w of HES for 7 days before 8Gy gamma irradiation, respectively. Histopathological evaluation was perfomred 24 hours after radiation.
RESULTS
RESULTS
Administration of hesperidin (50 mg/kg b.w, 7 days) before 2Gy of gamma irradiation led to remove inflammatory mononuclear cells in the portal space. Microscopic findings in the groups receiving two doses of hesperidin (50 and 100 mg/kg b.w, orally, 7 days), before 8Gy of gamma radiation, were similar in a way that extreme dilation of central veins to be seen, however, there was no capillarization.
CONCLUSION
CONCLUSIONS
HES can be offered as a suitable radio-protector in radiotherapy patients and radiation workers.
Identifiants
pubmed: 32158707
doi: 10.31661/jbpe.v0i0.832
pii: JBPE-10-1
pmc: PMC7036407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7-14Informations de copyright
Copyright: © 2020: Journal of Biomedical Physics and Engineering.
Références
Mutat Res. 2009 May 31;676(1-2):54-61
pubmed: 19486865
Adv Exp Med Biol. 1998;439:175-82
pubmed: 9781303
Ann N Y Acad Sci. 2000;899:44-60
pubmed: 10863528
Eur J Pharmacol. 2008 Jun 10;587(1-3):273-80
pubmed: 18485345
Farmaco. 1995 Sep;50(9):595-9
pubmed: 7495469
Nutr Cancer. 2016;68(1):29-39
pubmed: 26381129
Clin Chim Acta. 2005 Sep;359(1-2):89-100
pubmed: 15922998
J Pharm Pharmacol. 1994 Feb;46(2):118-22
pubmed: 8021799
FEBS Lett. 2004 May 21;566(1-3):39-42
pubmed: 15147865
Drug Discov Today. 2007 Oct;12(19-20):794-805
pubmed: 17933679
Int J Antimicrob Agents. 2005 Nov;26(5):343-56
pubmed: 16323269
J Med Food. 2012 May;15(5):419-27
pubmed: 22404572
Adv Exp Med Biol. 1998;439:103-16
pubmed: 9781298
J Biomed Phys Eng. 2017 Jun 01;7(2):127-136
pubmed: 28580334
Vascul Pharmacol. 2012 Nov-Dec;57(5-6):201-7
pubmed: 22967957
J Biomed Phys Eng. 2016 Dec 01;6(4):217-228
pubmed: 28144590
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):426-34
pubmed: 16690430
Int J Radiat Biol. 2012 Aug;88(8):613-8
pubmed: 22671307
Br J Nutr. 2009 Jan;101(2):263-9
pubmed: 18507878
Pharmacology. 2004 Aug;71(4):174-80
pubmed: 15240993
Phytother Res. 2001 Dec;15(8):655-69
pubmed: 11746857
Eur J Pharmacol. 2011 May 11;658(2-3):206-12
pubmed: 21371459
Arch Pharm Res. 2008 Jun;31(6):794-7
pubmed: 18563363
Int J Radiat Biol. 1994 Jan;65(1):27-33
pubmed: 7905906
Phytomedicine. 2005 Apr;12(4):285-93
pubmed: 15898706
J Biomed Phys Eng. 2016 Sep 01;6(3):165-174
pubmed: 27853724
Vojnosanit Pregl. 2014 Jan;71(1):60-5
pubmed: 24516992
Oncologist. 2010;15(4):360-71
pubmed: 20413641